GenArraytion Developed the First Commercially Available, Multi-Target Zika Virus Assay, which

PositiveID Implemented on Its Firefly Dx Prototype System and Successfully Detected the Zika Virus

DELRAY BEACH, Fla. — PositiveID Corporation (“PositiveID” or “Company”)

(OTCQB:PSID), a life sciences company focused on detection and diagnostics, announced today that it has added Dr. R. Paul Schaudies, the CEO and co-founder of GenArraytion, Inc. and an internationally recognized expert in biodefense, biotechnology and nanotechnology, to its Board of Advisors.

PositiveID’s Firefly Dx is designed to be a fully automated, lab quality, real-time device able to detect bio-threats at the point of need in minutes instead of hours. Firefly Dx has successfully detected multiple pathogens including Zika, a fever-causing virus transmitted by the Aedes Aegypti mosquito that can cause microcephaly, a serious congenital condition in which

babies are born with head and brain abnormalities.<